Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Date:3/11/2009

interests 85,007 11,653 86,002 11,790 Income tax expense (3,419) (469) (2,739) (2) (6,158) (844) Income before minority interests 81,588 11,184 79,844 10,946 Minority interests, net of tax (75) (10) (75) (10) Net income 81,513 11,174 79,769 10,936 Year Ended December 31, 2007 (unaudited), continued Actual Actual Adjustment Adjusted Adjusted GAAP GAAP Non-GAAP Non-GAAP RMB US$ RMB RMB US$ Net income per share: Basic and diluted 0.56 0.08 0.54 0.07 Basic weighted average number of shares 146,646,049 146,646,049 146,646,049 146,646,049 outstanding Effect of dilutive potential shares 68,993 68,993 68,993 68,993 Diluted weighted average number of shares outstanding 146,715,042 146,715,042 146,715,042 146,715,042 Net income per ADS: Basic and diluted 3.89 0.53 3.81 0.52 Basic weighted average number of ADSs 20,949,436 20,949,436 20,949,436 20,949,436 outstanding Effect of dilutive potential ADSs 9,856 9,856 9,856 9,856 Diluted weighted average number ADSs of outstanding 20,959,292 20,959,292 20,959,292 20,959,292

Notes to reconciliation of our GAAP statements of income to our adjusted statements of income:

     (1) To exclude share-based compensation expense.
     (2) To exclude reinvestment tax refund.



    For more i
'/>"/>
SOURCE  3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 

Related biology technology :

1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ), a leading pharmaceutical company,specializing in the development, manufacturing, a
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/2/2009)HOBOKEN, N.J., Dec. 2 According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopat
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...wing a devastating legal rebuke, the chief executi... to pursue other business interests. , ,Jeff Cason...provider of uninterruptible power supply services,...es. Former executive vice president Charley Eaton ...was sued for copyright infringement by UPS manufac...
...part of a new contract with General Motors , the ...ill design plug-in batteries for a Saturn hybrid...hnson Controls-Saft Advanced Power Solutions will... recharged from a typical household electrical out...n recent months for JCS. In August of 2006, the Eu...
... a Wisconsin entrepreneur what,s vital to the succ...o get a shopping list as a definitive answer. Find...lth insurance, protecting intellectual property, a...replies. , ,Holding down taxes? That,s on the shor...er depends on the entrepreneur. Those who aren,t y...
Other Biology Technology:High taxes and low rates of entrepreneurship - is there a relationship? 2High taxes and low rates of entrepreneurship - is there a relationship? 3
(Date:12/3/2009)Coral reef fish can undergo a personality change in warmer water, according to an intriguing new study suggesting that climate change may make some species more aggressive. , Experiments with two spe
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 1Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 3Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 4Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 5Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 6Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 7Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 8Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 9CareFusion Form 10 Registration Statement Declared Effective 52998 1CareFusion Form 10 Registration Statement Declared Effective 52998 2CareFusion Form 10 Registration Statement Declared Effective 52998 3CareFusion Form 10 Registration Statement Declared Effective 52998 4Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 1Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 2
...hange(TM) Software Access Local ...g. 13 BIO-key International,Inc. (OTC Bulletin Bo...utions and finger based biometric identification, ...ftware Module and its acceptance by several,agenci...This contract,represents BIO-key,s first with the ...
...on,Intelligence Corporation (OTC Bulletin Board: C...of electronic signature solutions for,business pro...recognized,leader in biometric signature verificat... three and six-month periods ended June 30, 2007. ...iod ended June 30,2007 increased 24% compared to $...
...o Equity, JERICHO, N.Y., Aug. 15 bioMETRX, Inc. ...d supplier of consumer,biometric products, today a... holders of its Series B common stock warrants tha... company by August 25, 2007. The Company notified...t,has elected to pay such holders $0.12 per share,...
Other Biology News:BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 2BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 2Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 4Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 5bioMETRX, Inc. Calls Series B Warrants 2
...Description: Proteinase K is a highly active and s...ations purified from the fungus T. album. It cleav...up of N-substituted hydrophobic aliphatic and arom...e protease. Proteinase K is useful in purifying hi...
..., high throughput, water bath thermal cycler capab...oplates. This equates to 9,216 reactions per run w...y transfers a basket of plates between three water... are considerably faster than those of peltier blo...
...tidine Dideoxycytidine is a cytidine analog that ...viral activity. Immunogen: Chemical / Small Mol...ficity of the ddC antiserum was determined by calc...ddC analog at the 50% intercept of the respective ...
MSC.12 class II safety cabinet (Type A1) - CE Marked (230V / 50Hz) from Thermo Scientific
Biology Products: